【DT新材料】 获悉 ， 8月3日晚间， 帕瓦新能源股份有限公司 公告称，公司于2025年8月1日收到公安机 关出具的《立案决定书》， 公司共同实际控制人之一、董事张宝涉嫌职务侵占被公安机关立案侦查。 此次张宝被立案侦查或早有预兆，在其被立案调查两个多月前，他刚辞去了董事长、总经理等职务。 5月22日， 帕瓦新能源 发布公告，董事长兼总经理张宝因个人身体原因辞去职务，并不再担任公司法 定代表人。张宝的辞职自2025年5月21日起生效，但他将继续担任公司董事及战略委员会主任委员等 职务。在同一天的董事会上，公司选举王宝良为新董事长，并聘任其为总经理，任期自董事会审议通过 之日起至第三届董事会任期届满。王宝良在2016年9月至2022年10月曾任公司董事长，具备丰富的企 业管理经验。 7月13日，ST帕瓦在回复上交所问询函中透露，根据张宝6月出具的《资金占用情况说明》， 张宝通过 供应商占用公司资金1.4亿元，占用销售货款4991.88万元，合计占用公司资金本金1.91亿元 ； 按照 公司对上述供应商年度支付金额分摊，其中2022 年度占用7403.2万元，2023 年度占用8538.62万 元，2024年度占用 ...

Core Points - ST Pava announced on August 3 that one of its actual controllers, Zhang Bao, is under investigation for embezzlement by public security authorities, but the company's control and operations remain normal [1] - The company specializes in the production, research, and sales of lithium-ion battery ternary cathode material precursors for electric vehicles and was listed on the Sci-Tech Innovation Board in September 2022 [1] - Due to a negative audit report from Tianjian Accounting Firm regarding internal controls for the 2024 financial report, ST Pava's stock was placed under risk warning, changing its name to ST Pava [1] - The company acknowledged management issues leading to unfair pricing with suppliers, resulting in overpayment of 180 million yuan, for which Zhang Bao has committed to recover the amount and bear joint liability for the losses [1] Company Overview - ST Pava was established in July 2014 and focuses on electric vehicle battery materials [1] - Zhang Bao, aged 54, holds a PhD and has been with the company since September 2019, serving as general manager and chairman [2] - As of June 24, Zhang Bao is the second-largest shareholder, holding 16.56 million shares, accounting for 10.41% of the company [3] Financial and Operational Status - As of August 1, ST Pava's stock price was 10.01 yuan per share, with a total market capitalization of 1.6 billion yuan [6] - The company reported that Zhang Bao occupied 191 million yuan of company funds, with 30 million yuan already returned [4][5] - The company is actively pursuing the recovery of the occupied funds and has communicated with Zhang Bao to establish a repayment plan [5]

Core Viewpoint - ST Pava's actual controller, Zhang Bao, is under investigation for embezzlement, which has raised concerns but the company asserts that its operations remain normal and unaffected [2][4]. Group 1: Investigation Details - On August 1, ST Pava received a notice from the public security bureau regarding the investigation of Zhang Bao for embezzlement [2]. - The company reported that other board members and senior management are performing their duties normally, and there has been no change in control [4]. Group 2: Financial Implications - Zhang Bao is accused of misappropriating company funds totaling 191 million yuan [5]. - As of the announcement date, the company has received 30 million yuan back from Zhang Bao and is actively pursuing the recovery of the remaining funds [8]. Group 3: Company Background - ST Pava focuses on the research, production, and sales of new energy battery materials, particularly in lithium-ion and sodium-ion battery cathode materials [8]. - As of August 1, ST Pava's stock price was 10.01 yuan per share, with a total market capitalization of 1.6 billion yuan [8].

ST帕瓦(688184.SH)公告称，公司于2025年8月1日收到公安机关出具的《立案决定书》，公司共同实际 控制人之一、董事张宝涉嫌职务侵占被公安机关立案侦查。目前公司其他董事、监事和高级管理人员均 正常履职，公司控制权未发生变化，生产经营情况正常。公司将持续关注上述事项的进展情况，并及时 履行信息披露义务。 ...

Core Viewpoint - The article discusses allegations of financial fraud against Huaxi Biological (688363.SH) and its controlling shareholder, Huaxi Xinyu Investment Co., Ltd. The company has denied these allegations and claims that the accuser has a history of embezzlement [1][2]. Group 1: Allegations and Responses - A former employee, referred to as Mr. Li, accused Huaxi Biological of financial fraud, including concealing the holding of 30 million shares of Jinzhou Bank and fabricating revenue and inflated expenses in 2017 [1][4]. - Huaxi Biological issued a statement claiming that Mr. Li had previously committed embezzlement and that his allegations are unfounded [1][2]. - The company stated that Mr. Li had reported similar accusations during the IPO review process in 2019, which were investigated and found to be false [2]. Group 2: Financial Practices and Regulatory Actions - Huaxi Xinyu issued exchangeable bonds in May 2017, and the financial data disclosed during this process was later found to be inaccurate, leading to a warning from the Beijing Securities Regulatory Bureau [3]. - The warning was linked to Mr. Li's allegations, as he provided evidence to the regulatory body [4]. - Huaxi Xinyu's financial practices included adjustments to costs and expenses based on actual business conditions, which were reported in compliance with tax regulations [2]. Group 3: Shareholding and Legal Disputes - As of the first quarter of 2025, Huaxi Xinyu holds 283.5 million shares of Huaxi Biological, representing a 58.86% stake [1]. - There have been legal disputes related to the shareholding of Jinzhou Bank, where Huaxi Xinyu was involved in a lawsuit concerning the holding of 30 million shares on behalf of another entity [5].

Core Viewpoint - A recent allegation by an individual named "David" claims that Huaxi Biological (688363.SH) is involved in illegal activities, including financial fraud. The company has strongly denied these claims, stating that the information is fabricated and defamatory [1][2]. Group 1 - The individual "David" claims to have been a special assistant to the CEO of Huaxi Biological and has written a lengthy document detailing alleged misconduct, although only the table of contents and summaries have been published [1]. - Huaxi Biological issued a statement on July 26, asserting that the allegations are false and originated from an overseas website. The company emphasized that the claims are entirely fabricated [1]. - The individual behind the allegations, Li, previously held a position at Huaxi and was involved in a financial misconduct case where he embezzled 9 million yuan. This incident was reported to the police, leading to legal action against him [1][2]. Group 2 - Huaxi Biological included a notice of the legal case and Li's apology letter in their statement, where Li admitted to serious violations during a bond issuance process [2]. - The company has reported the defamatory claims to law enforcement and is pursuing legal action against the individual and those spreading the false information [2].

Core Viewpoint - The company has issued a stern statement regarding the dissemination of false information that severely damages its reputation, asserting that it will pursue legal action against the perpetrators [1][3]. Group 1: Incident Overview - On July 26, the company announced that it discovered serious false information about itself being circulated on foreign websites, which it claims is fabricated and maliciously distorts facts [1]. - The individual responsible for the false information, identified as Li, previously served as the marketing director at Huaxi Xinyu Investment Co., Ltd. for 18 months [1]. - In 2018, Li fraudulently obtained 9 million yuan (approximately 1.3 million USD) that was supposed to be paid to a brokerage, leading to his exposure and subsequent legal action [1]. Group 2: Legal Actions - The company has reported the matter to law enforcement and is pursuing legal accountability for defamation against those spreading the false information [1][3]. - The police have initiated an investigation into Li's actions, which fall under the crime of embezzlement as per Article 271 of the Criminal Law of the People's Republic of China [1]. Group 3: Apology and Compensation - Li issued a letter of apology to the company, acknowledging his wrongdoing and expressing regret for the negative impact on the company's reputation [9]. - In his apology, Li promised to return the embezzled 9 million yuan and offered an additional 1.5 million yuan (approximately 220,000 USD) as compensation for his actions [9].

Core Viewpoint - A former employee of Huaxi Biological, claiming to be "David," has made serious allegations of financial misconduct against the company, which Huaxi Biological has strongly denied, stating that the claims are false and defamatory [2][4][9]. Group 1: Allegations and Responses - "David" claims to have been a senior assistant to the CEO and has written extensively about the company, although only a table of contents and summaries have been published [2]. - Huaxi Biological responded via its official Weibo, asserting that the allegations are fabricated and have been reported to the authorities [4][9]. - The individual behind the allegations, identified as Li, previously worked at Huaxi and was involved in a financial misconduct case where he embezzled 9 million yuan (approximately 1.3 million USD) [5]. Group 2: Legal Actions and Company Stance - Huaxi Biological has stated that it will pursue legal action against the individual for defamation and has already reported the matter to law enforcement [9]. - The company provided evidence of Li's previous misconduct, including a letter of apology where he admitted to serious violations during a bond issuance process [7][5]. - Huaxi Biological emphasized that the allegations are morally baseless and have severely damaged its reputation [4][9].

Performance Forecast - The company expects a net loss attributable to shareholders of between 5 million and 10 million yuan for the current reporting period, a decrease of 119.39% compared to a profit of 25.79 million yuan in the same period last year [1] - The net profit after deducting non-recurring gains and losses is projected to be a loss of between 8 million and 13 million yuan, down 134.27% from a profit of 23.35 million yuan in the previous year [1] - Basic earnings per share are expected to be a loss of 0.02 to 0.04 yuan, compared to earnings of 0.10 yuan per share in the same period last year [1] Reasons for Performance Change - The company reported that a sales employee was suspected of embezzlement, involving the forgery of customer seals and sales contracts, which has led to a significant impact on the company's financial statements [2] - The preliminary self-examination indicated that the embezzlement could affect the company's net profit by approximately 29.35 million yuan for the first quarter of 2025 [2] - The company's revenue for the first quarter of 2025 is estimated to be around 1.407 billion yuan, slightly increasing after accounting for the impact of the aforementioned incident [2] Communication with Auditors - The performance forecast has not been audited by registered accountants [2]

Core Viewpoint - The article discusses the allegations against former executives of Jiaoda Onlly for illegal insurance policy cancellations and embezzlement, detailing the company's response and ongoing legal actions [1][3][4]. Group 1: Allegations and Legal Actions - Jiaoda Onlly reported that it discovered former executives' illegal insurance cancellations and has been gathering evidence to support its claims, leading to multiple lawsuits [1][3]. - The company filed a criminal report with the Shanghai Public Security Bureau on June 24, which was accepted, but later received a notice of non-filing on July 10 [3][4]. - The company plans to appeal the non-filing decision to higher authorities [4]. Group 2: Financial Irregularities - The company identified abnormal insurance purchases starting from November 23, 2022, revealing a total of 12.84 million yuan in insurance payments from 2018 without corresponding policy contracts [6][7]. - Five former executives allegedly received a total of 16.94 million yuan through insurance policy cancellations, which were not approved by the board or shareholders, indicating potential misconduct [7][9]. - The former executives claimed that the insurance purchases and cancellations were part of their compensation, which the company disputes as lacking proper authorization [7][9]. Group 3: Company Background and Governance - Jiaoda Onlly, established in 1997 and listed in 2001, is the first publicly traded company in China's health food industry, with a market capitalization of 7.5 billion yuan as of July 10 [9][10]. - Following a change in control in August 2022, the new controlling shareholder conducted a review of the company's financials, leading to allegations of financial misreporting [10][11]. - The company’s governance structure requires board and shareholder approval for executive compensation, which was not adhered to in the case of the disputed insurance transactions [12].